These publications and articles are available for immediate purchase and download. Payment is accepted via VISA, Mastercard, and American Express.We offer special rates for startup companies; academic and tech transfer programs; clinical trial sites; and individual clinicians. Please contact us at:

NeuroPerspectiveborder.jpg NeuroPerspective

Our bimonthly journal covering the cutting-edge therapies being developed for disorders of the central nervous system, including Alzheimer's, Parkinson's, TBI, schizophrenia, and depression--and the companies pursuing them. It enjoys worldwide readership and kudoes for its 'no-holds-barred' evaluations. One year, six issue subscription cycle. Global corporate, academic, startup, and individual rates available: email us at

NL2016-17 NeuroLicensing 2016-17 $3,500.00

NeuroLicensing 2016-17 is NIRís completely revised and updated review of current trends in CNS deal parameters, and candid assessments of the major and midsize companies involved in CNS licensing. Licensing agendas and performance are appraised. Two new sections are added to this year's edition, regarding partner aspirations and rankings in specific therapeutic areas. NL 2016-17 provides a vital targeting resource for licensing efforts on both sides of the transaction, both licensors and licensees. Released August 2016. $3500 for a five-user (within one Company) subscription license. 99 pages. Available for immediate download.

Single issues of NeuroPerspective and selected features from NeuroPerspective and our annual publications can be purchased 'a la carte.' Click on the desired category to see the choices that are currently available.